Featured Research

from universities, journals, and other organizations

Chemotherapy Given Directly To The Liver Improves Survival For Patients With Colorectal Cancer

Date:
February 28, 2006
Source:
American Society of Clinical Oncology
Summary:
A new study shows that patients whose colorectal cancer has spread to the liver who received an approach called hepatic arterial infusion (HAI) -- the administration of chemotherapy directly to the liver through a pump in the abdomen -- fare better than those who received traditional, intravenous chemotherapy. Researchers found that the patients on the HAI therapy lived longer and had better quality of life than those receiving systemic therapy. The study will be published online February 27 in the Journal of Clinical Oncology.

Alexandria, VA--A new study shows that patients whose colorectal cancer has spread to the liver who received an approach called hepatic arterial infusion (HAI)-- the administration of chemotherapy directly to the liver through a pump in the abdomen--fare better than those who received traditional, intravenous chemotherapy. Researchers found that the patients on the HAI therapy lived longer and had better quality of life than those receiving systemic therapy. The study will be published online February 27 in the Journal of Clinical Oncology.

Related Articles


"This study demonstrates that hepatic arterial infusion therapy extends survival and improves quality of life in patients with colorectal cancer that has spread to the liver," said Nancy E. Kemeny, MD, an Attending Physician in the Department of Medicine at Memorial Sloan-Kettering Cancer Center and the study's lead author. "These positive findings are particularly important, given that metastasis to the liver occurs in 60% of patients with metastatic colorectal cancer, and most patients with these liver tumors eventually die of their disease."

Several smaller studies have previously compared outcomes of HAI with systemic chemotherapy, but this is the first large study that had no crossover between the groups, meaning that none of the patients in the systemic group received HAI therapy.

In the multi-institutional trial by researchers from the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group, 135 patients were assigned randomly to receive either HAI or systemic chemotherapy. All of the patients needed to undergo surgical removal (resection) of their primary tumors in the colon or rectum before initiating chemotherapy. Patients receiving HAI then underwent a surgical procedure to have a chemotherapy pump inserted into their abdomen. (This procedure can sometimes be done laparoscopically.)

Researchers found that patients receiving HAI lived longer than those receiving systemic chemotherapy, with a median survival of 24 versus 20 months. In addition, patients receiving HAI had better response rates (47% versus 24%), and longer time to disease progression in the liver (9.8 months versus 7.3 months).

While patients receiving systemic chemotherapy experienced the usual treatment-associated side effects such as diarrhea, decreased white blood cell counts, and hair loss, patients receiving HAI did not. However, because patients on the HAI regimen experienced mild toxicity to the liver, patients' liver functions were monitored closely throughout the duration of treatment to prevent the toxicity from becoming more severe.

For both methods of treatment, women fared better than men, with median survival in the HAI group of 29.4 and 20.1 months for women and men, respectively, and in the systemic group it was 22.0 and 18.3 months.

Because the research began in 1996, before chemotherapy drugs such as irinotecan and oxaliplatin were available, both sets of patients received fluorouracil and leucovorin. Both groups had access to the newer drugs as they became available. Dr. Kemeny noted that studies are currently underway using HAI therapy in combination with newer drugs, and response rates appear to be even higher. Furthermore, the addition of HAI therapy is also being investigated in patients with primary liver cancer.

###

"Hepatic Arterial Infusion Versus Systemic Therapy for Hepatic Metastases From Colorectal Cancer: A Randomized Trial of Efficacy, Quality of Life, and Molecular Markers (CALGB 9481)." Nancy E. Kemeny, Memorial Sloan-Kettering Cancer Center, New York, NY.

A consumer information piece on this study can be found on ASCO's patient website, People Living With Cancer.org, at www.plwc.org/CancerAdvances. For additional information on the diagnosis and treatment of colorectal and liver cancer including staging illustrations, visit www.plwc.org/colorectal and www.plwc.org/liver.

The Journal of Clinical Oncology is the semi-monthly peer-reviewed journal of the American Society of Clinical Oncology (ASCO), the world's leading professional society representing physicians who treat people with cancer.



Story Source:

The above story is based on materials provided by American Society of Clinical Oncology. Note: Materials may be edited for content and length.


Cite This Page:

American Society of Clinical Oncology. "Chemotherapy Given Directly To The Liver Improves Survival For Patients With Colorectal Cancer." ScienceDaily. ScienceDaily, 28 February 2006. <www.sciencedaily.com/releases/2006/02/060228085333.htm>.
American Society of Clinical Oncology. (2006, February 28). Chemotherapy Given Directly To The Liver Improves Survival For Patients With Colorectal Cancer. ScienceDaily. Retrieved December 20, 2014 from www.sciencedaily.com/releases/2006/02/060228085333.htm
American Society of Clinical Oncology. "Chemotherapy Given Directly To The Liver Improves Survival For Patients With Colorectal Cancer." ScienceDaily. www.sciencedaily.com/releases/2006/02/060228085333.htm (accessed December 20, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Saturday, December 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

The Best Tips to Curb Holiday Carbs

The Best Tips to Curb Holiday Carbs

Buzz60 (Dec. 19, 2014) It's hard to resist those delicious but fattening carbs we all crave during the winter months, but there are some ways to stay satisfied without consuming the extra calories. Vanessa Freeman (@VanessaFreeTV) has the details. Video provided by Buzz60
Powered by NewsLook.com
Sierra Leone Bikers Spread the Message to Fight Ebola

Sierra Leone Bikers Spread the Message to Fight Ebola

AFP (Dec. 19, 2014) More than 100 motorcyclists hit the road to spread awareness messages about Ebola. Nearly 7,000 people have now died from the virus, almost all of them in west Africa, according to the World Health Organization. Video provided by AFP
Powered by NewsLook.com
Researchers Test Colombian Village With High Alzheimer's Rates

Researchers Test Colombian Village With High Alzheimer's Rates

AFP (Dec. 19, 2014) In Yarumal, a village in N. Colombia, Alzheimer's has ravaged a disproportionately large number of families. A genetic "curse" that may pave the way for research on how to treat the disease that claims a new victim every four seconds. Duration: 02:42 Video provided by AFP
Powered by NewsLook.com
Double-Amputee Becomes First To Move Two Prosthetic Arms With His Mind

Double-Amputee Becomes First To Move Two Prosthetic Arms With His Mind

Buzz60 (Dec. 19, 2014) A double-amputee makes history by becoming the first person to wear and operate two prosthetic arms using only his mind. Jen Markham has the story. Video provided by Buzz60
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins